Julia Lainster

Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we will be discussing his insights on two recently introduced health policy legislation aimed at improving telehealth access and expediting lung cancer

Cancer biology has traditionally emphasized the competitive nature of tumor cells as they compete fiercely for limited resources. However, recent research led by Carlos Carmona-Fontaine at New York University has unveiled a groundbreaking and surprising discovery that cancer cells also exhibit

In the midst of technological advancements, medical imaging tests like X-rays, MRIs, mammograms, and CT scans have become indispensable tools in modern diagnostics; however, questions about the safety and health risks associated with these tests frequently emerge. Radiation exposure is a common

In a groundbreaking study published in JAMA, researchers from Mass General Brigham have demonstrated the potential of artificial intelligence (AI) to revolutionize patient screening for clinical trials. The study, led by co-senior authors Samuel (Sandy) Aronson and Alexander Blood, focused on a

Telehealth is revolutionizing the healthcare industry by providing sustainable solutions that enhance emergency and disaster care. As technology advances, telemedicine allows healthcare providers to offer remote consultations and medical support, reducing the need for in-person visits. This

The field of bioprinting is rapidly evolving, with bioinks playing a crucial role in the development of 3D printed living tissues. Bioinks, which incorporate live cells and bioactive molecules, are essential for creating tissue models that can revolutionize medicine, biology, and personalized

In a significant step toward understanding and combating childhood cancers and congenital disorders, the Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH), has released two comprehensive new datasets. Focusing on childhood

In an unexpected turn of events that sent ripples through the biotechnology sector, Pliant Therapeutics' shares experienced a dramatic plunge after the company voluntarily halted the Phase 2b/3 trial of its experimental fibrosis drug, bexotegrast. The decision, advised by a clinical trial

Fosun Pharmaceutical, a leading Chinese pharmaceutical conglomerate, recently attempted to take full control of its biopharma subsidiary, Henlius Biotech, by purchasing the remaining minority shares. This strategic move aimed to consolidate Henlius under Fosun's complete ownership, leveraging

Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of p